Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study
Identifieur interne :
001B73 ( PascalFrancis/Corpus );
précédent :
001B72;
suivant :
001B74
Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study
Auteurs : H. Allain ;
F. Le Coz ;
F. Goulley ;
F. Brunet-Bourgin ;
Y. Loria ;
D. Bentue-Ferrer ;
R. Decombe ;
J.-M. Reymann ;
P. Chaumet-Riffaud ;
J.-M. GandonSource :
-
International journal of clinical pharmacology, therapy and toxicology : (1980) [ 0174-4879 ] ; 1991.
RBID : Pascal:91-0549078
Descripteurs français
- Pascal (Inist)
- Antiparkinsonien,
Stimulant dopaminergique,
Association médicamenteuse,
Forme pharmaceutique,
Traitement,
Chimiothérapie,
Homme,
Système nerveux pathologie,
Récepteur dopaminergique D2,
Forme libération contrôlée,
Parkinson maladie,
Essai thérapeutique contrôlé,
Dopa,
Bromocriptine,
Essai clinique.
English descriptors
- KwdEn :
- Antiparkinson agent,
Bromocryptine,
Chemotherapy,
Clinical trial,
Controlled release form,
Controlled therapeutic trial,
D2 Dopamine receptor,
Dopa,
Dopamine agonist,
Dosage form,
Drug combination,
Human,
Nervous system diseases,
Parkinson disease,
Treatment.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
| A01 | 01 | 1 | | @0 0174-4879 |
|---|
| A02 | 01 | | | @0 IJCPB5 |
|---|
| A03 | | 1 | | @0 Int. j. clin. pharmacol. ther. toxicol. : (1980) |
|---|
| A05 | | | | @2 29 |
|---|
| A06 | | | | @2 8 |
|---|
| A08 | 01 | 1 | ENG | @1 Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study |
|---|
| A11 | 01 | 1 | | @1 ALLAIN (H.) |
|---|
| A11 | 02 | 1 | | @1 LE COZ (F.) |
|---|
| A11 | 03 | 1 | | @1 GOULLEY (F.) |
|---|
| A11 | 04 | 1 | | @1 BRUNET-BOURGIN (F.) |
|---|
| A11 | 05 | 1 | | @1 LORIA (Y.) |
|---|
| A11 | 06 | 1 | | @1 BENTUE-FERRER (D.) |
|---|
| A11 | 07 | 1 | | @1 DECOMBE (R.) |
|---|
| A11 | 08 | 1 | | @1 REYMANN (J.-M.) |
|---|
| A11 | 09 | 1 | | @1 CHAUMET-RIFFAUD (P.) |
|---|
| A11 | 10 | 1 | | @1 GANDON (J.-M.) |
|---|
| A14 | 01 | | | @1 Univ. hosp., dep. neurology neuropharmacology @2 Rennes 35033 @3 FRA @Z A11011000 |
|---|
| A20 | | | | @1 314-322 |
|---|
| A21 | | | | @1 1991 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 15902 @3 354000012495080050 |
|---|
| A44 | | | | @0 0000 |
|---|
| A45 | | | | @0 1 p. |
|---|
| A47 | 01 | 1 | | @0 91-0549078 |
|---|
| A60 | | | | @1 P |
|---|
| A61 | | | | @0 A |
|---|
| A64 | | 1 | | @0 International journal of clinical pharmacology, therapy and toxicology : (1980) |
|---|
| A66 | 01 | | | @0 DEU |
|---|
| C02 | 01 | X | | @0 002B02B06 |
|---|
| C03 | 01 | X | FRE | @0 Antiparkinsonien |
|---|
| C03 | 02 | X | FRE | @0 Stimulant dopaminergique |
|---|
| C03 | 03 | X | FRE | @0 Association médicamenteuse |
|---|
| C03 | 04 | X | FRE | @0 Forme pharmaceutique |
|---|
| C03 | 05 | X | FRE | @0 Traitement |
|---|
| C03 | 06 | X | FRE | @0 Chimiothérapie |
|---|
| C03 | 07 | X | FRE | @0 Homme |
|---|
| C03 | 08 | X | FRE | @0 Système nerveux pathologie |
|---|
| C03 | 09 | X | FRE | @0 Récepteur dopaminergique D2 |
|---|
| C03 | 10 | X | FRE | @0 Forme libération contrôlée |
|---|
| C03 | 11 | X | FRE | @0 Parkinson maladie |
|---|
| C03 | 12 | X | FRE | @0 Essai thérapeutique contrôlé |
|---|
| C03 | 13 | X | FRE | @0 Dopa |
|---|
| C03 | 14 | X | FRE | @0 Bromocriptine |
|---|
| C03 | 15 | X | FRE | @0 Essai clinique |
|---|
| C03 | 01 | X | ENG | @0 Antiparkinson agent |
|---|
| C03 | 02 | X | ENG | @0 Dopamine agonist |
|---|
| C03 | 03 | X | ENG | @0 Drug combination |
|---|
| C03 | 04 | X | ENG | @0 Dosage form |
|---|
| C03 | 05 | X | ENG | @0 Treatment |
|---|
| C03 | 06 | X | ENG | @0 Chemotherapy |
|---|
| C03 | 07 | X | ENG | @0 Human |
|---|
| C03 | 08 | X | ENG | @0 Nervous system diseases |
|---|
| C03 | 09 | X | ENG | @0 D2 Dopamine receptor |
|---|
| C03 | 10 | X | ENG | @0 Controlled release form |
|---|
| C03 | 11 | X | ENG | @0 Parkinson disease |
|---|
| C03 | 12 | X | ENG | @0 Controlled therapeutic trial |
|---|
| C03 | 13 | X | ENG | @0 Dopa |
|---|
| C03 | 14 | X | ENG | @0 Bromocryptine |
|---|
| C03 | 15 | X | ENG | @0 Clinical trial |
|---|
| C03 | 01 | X | SPA | @0 Antiparkinsoniano |
|---|
| C03 | 02 | X | SPA | @0 Estimulante dopaminérgico |
|---|
| C03 | 03 | X | SPA | @0 Asociación medicamentosa |
|---|
| C03 | 04 | X | SPA | @0 Forma farmacéutica |
|---|
| C03 | 05 | X | SPA | @0 Tratamiento |
|---|
| C03 | 06 | X | SPA | @0 Quimioterapia |
|---|
| C03 | 07 | X | SPA | @0 Hombre |
|---|
| C03 | 08 | X | SPA | @0 Sistema nervioso patología |
|---|
| C03 | 09 | X | SPA | @0 Receptor dopaminérgico D2 |
|---|
| C03 | 10 | X | SPA | @0 Forma liberación controlada |
|---|
| C03 | 11 | X | SPA | @0 Parkinson enfermedad |
|---|
| C03 | 12 | X | SPA | @0 Ensayo terapéutico controlado |
|---|
| C03 | 13 | X | SPA | @0 Dopa |
|---|
| C03 | 15 | X | SPA | @0 Ensayo clínico |
|---|
| N21 | | | | @1 137 |
|---|
| N82 | | | | @1 NIM |
|---|
|
|---|
Format Inist (serveur)
| NO : | PASCAL 91-0549078 INIST |
|---|
| ET : | Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study |
|---|
| AU : | ALLAIN (H.); LE COZ (F.); GOULLEY (F.); BRUNET-BOURGIN (F.); LORIA (Y.); BENTUE-FERRER (D.); DECOMBE (R.); REYMANN (J.-M.); CHAUMET-RIFFAUD (P.); GANDON (J.-M.) |
|---|
| AF : | Univ. hosp., dep. neurology neuropharmacology/Rennes 35033/France (A11011000) |
|---|
| DT : | Publication en série; Niveau analytique |
|---|
| SO : | International journal of clinical pharmacology, therapy and toxicology : (1980); ISSN 0174-4879; Coden IJCPB5; Allemagne; Da. 1991; Vol. 29; No. 8; Pp. 314-322; Bibl. 1 p. |
|---|
| LA : | Anglais |
|---|
| CC : | 002B02B06 |
|---|
| FD : | Antiparkinsonien; Stimulant dopaminergique; Association médicamenteuse; Forme pharmaceutique; Traitement; Chimiothérapie; Homme; Système nerveux pathologie; Récepteur dopaminergique D2; Forme libération contrôlée; Parkinson maladie; Essai thérapeutique contrôlé; Dopa; Bromocriptine; Essai clinique |
|---|
| ED : | Antiparkinson agent; Dopamine agonist; Drug combination; Dosage form; Treatment; Chemotherapy; Human; Nervous system diseases; D2 Dopamine receptor; Controlled release form; Parkinson disease; Controlled therapeutic trial; Dopa; Bromocryptine; Clinical trial |
|---|
| SD : | Antiparkinsoniano; Estimulante dopaminérgico; Asociación medicamentosa; Forma farmacéutica; Tratamiento; Quimioterapia; Hombre; Sistema nervioso patología; Receptor dopaminérgico D2; Forma liberación controlada; Parkinson enfermedad; Ensayo terapéutico controlado; Dopa; Ensayo clínico |
|---|
| LO : | INIST-15902 |
|---|
| ID : | 91-0549078 |
|---|
Links to Exploration step
Pascal:91-0549078
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author><author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F." last="Le Coz">F. Le Coz</name>
</author><author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F." last="Goulley">F. Goulley</name>
</author><author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F." last="Brunet-Bourgin">F. Brunet-Bourgin</name>
</author><author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y." last="Loria">Y. Loria</name>
</author><author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
</author><author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R." last="Decombe">R. Decombe</name>
</author><author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J.-M." last="Reymann">J.-M. Reymann</name>
</author><author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P." last="Chaumet-Riffaud">P. Chaumet-Riffaud</name>
</author><author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J.-M." last="Gandon">J.-M. Gandon</name>
</author><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">91-0549078</idno>
<date when="1991">1991</date>
<idno type="stanalyst">PASCAL 91-0549078 INIST</idno>
<idno type="RBID">Pascal:91-0549078</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B73</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study</title>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author><author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F." last="Le Coz">F. Le Coz</name>
</author><author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F." last="Goulley">F. Goulley</name>
</author><author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F." last="Brunet-Bourgin">F. Brunet-Bourgin</name>
</author><author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y." last="Loria">Y. Loria</name>
</author><author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D." last="Bentue-Ferrer">D. Bentue-Ferrer</name>
</author><author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R." last="Decombe">R. Decombe</name>
</author><author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J.-M." last="Reymann">J.-M. Reymann</name>
</author><author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P." last="Chaumet-Riffaud">P. Chaumet-Riffaud</name>
</author><author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J.-M." last="Gandon">J.-M. Gandon</name>
</author><series><title level="j" type="main">International journal of clinical pharmacology, therapy and toxicology : (1980)</title>
<title level="j" type="abbreviated">Int. j. clin. pharmacol. ther. toxicol. : (1980)</title>
<idno type="ISSN">0174-4879</idno>
<imprint><date when="1991">1991</date>
</imprint><seriesStmt><title level="j" type="main">International journal of clinical pharmacology, therapy and toxicology : (1980)</title>
<title level="j" type="abbreviated">Int. j. clin. pharmacol. ther. toxicol. : (1980)</title>
<idno type="ISSN">0174-4879</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Bromocryptine</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Controlled release form</term>
<term>Controlled therapeutic trial</term>
<term>D2 Dopamine receptor</term>
<term>Dopa</term>
<term>Dopamine agonist</term>
<term>Dosage form</term>
<term>Drug combination</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Stimulant dopaminergique</term>
<term>Association médicamenteuse</term>
<term>Forme pharmaceutique</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Système nerveux pathologie</term>
<term>Récepteur dopaminergique D2</term>
<term>Forme libération contrôlée</term>
<term>Parkinson maladie</term>
<term>Essai thérapeutique contrôlé</term>
<term>Dopa</term>
<term>Bromocriptine</term>
<term>Essai clinique</term>
</keywords><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0174-4879</s0>
</fA01><fA02 i1="01"><s0>IJCPB5</s0>
</fA02><fA03 i2="1"><s0>Int. j. clin. pharmacol. ther. toxicol. : (1980)</s0>
</fA03><fA08 i1="01" i2="1" l="ENG"><s1>Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study</s1>
</fA08><fA11 i1="01" i2="1"><s1>ALLAIN (H.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>LE COZ (F.)</s1>
</fA11><fA11 i1="03" i2="1"><s1>GOULLEY (F.)</s1>
</fA11><fA11 i1="04" i2="1"><s1>BRUNET-BOURGIN (F.)</s1>
</fA11><fA11 i1="05" i2="1"><s1>LORIA (Y.)</s1>
</fA11><fA11 i1="06" i2="1"><s1>BENTUE-FERRER (D.)</s1>
</fA11><fA11 i1="07" i2="1"><s1>DECOMBE (R.)</s1>
</fA11><fA11 i1="08" i2="1"><s1>REYMANN (J.-M.)</s1>
</fA11><fA11 i1="09" i2="1"><s1>CHAUMET-RIFFAUD (P.)</s1>
</fA11><fA11 i1="10" i2="1"><s1>GANDON (J.-M.)</s1>
</fA11><fA14 i1="01"><s1>Univ. hosp., dep. neurology neuropharmacology</s1>
<s2>Rennes 35033</s2>
<s3>FRA</s3>
<sZ>A11011000</sZ>
</fA14><fA20><s1>314-322</s1>
</fA20><fA21><s1>1991</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>15902</s2>
<s3>354000012495080050</s3>
</fA43><fA44><s0>0000</s0>
</fA44><fA45><s0>1 p.</s0>
</fA45><fA47 i1="01" i2="1"><s0>91-0549078</s0>
</fA47><fA64 i2="1"><s0>International journal of clinical pharmacology, therapy and toxicology : (1980)</s0>
</fA64><fA66 i1="01"><s0>DEU</s0>
</fA66><fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Forme pharmaceutique</s0>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
</fC03><fC03 i1="10" i2="X" l="FRE"><s0>Forme libération contrôlée</s0>
</fC03><fC03 i1="11" i2="X" l="FRE"><s0>Parkinson maladie</s0>
</fC03><fC03 i1="12" i2="X" l="FRE"><s0>Essai thérapeutique contrôlé</s0>
</fC03><fC03 i1="13" i2="X" l="FRE"><s0>Dopa</s0>
</fC03><fC03 i1="14" i2="X" l="FRE"><s0>Bromocriptine</s0>
</fC03><fC03 i1="15" i2="X" l="FRE"><s0>Essai clinique</s0>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Dopamine agonist</s0>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Drug combination</s0>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Dosage form</s0>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
</fC03><fC03 i1="10" i2="X" l="ENG"><s0>Controlled release form</s0>
</fC03><fC03 i1="11" i2="X" l="ENG"><s0>Parkinson disease</s0>
</fC03><fC03 i1="12" i2="X" l="ENG"><s0>Controlled therapeutic trial</s0>
</fC03><fC03 i1="13" i2="X" l="ENG"><s0>Dopa</s0>
</fC03><fC03 i1="14" i2="X" l="ENG"><s0>Bromocryptine</s0>
</fC03><fC03 i1="15" i2="X" l="ENG"><s0>Clinical trial</s0>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Forma farmacéutica</s0>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
</fC03><fC03 i1="10" i2="X" l="SPA"><s0>Forma liberación controlada</s0>
</fC03><fC03 i1="11" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
</fC03><fC03 i1="12" i2="X" l="SPA"><s0>Ensayo terapéutico controlado</s0>
</fC03><fC03 i1="13" i2="X" l="SPA"><s0>Dopa</s0>
</fC03><fC03 i1="15" i2="X" l="SPA"><s0>Ensayo clínico</s0>
</fC03><fN21><s1>137</s1>
</fN21><fN82><s1>NIM</s1>
</fN82><server><NO>PASCAL 91-0549078 INIST</NO>
<ET>Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study</ET>
<AU>ALLAIN (H.); LE COZ (F.); GOULLEY (F.); BRUNET-BOURGIN (F.); LORIA (Y.); BENTUE-FERRER (D.); DECOMBE (R.); REYMANN (J.-M.); CHAUMET-RIFFAUD (P.); GANDON (J.-M.)</AU>
<AF>Univ. hosp., dep. neurology neuropharmacology/Rennes 35033/France (A11011000)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>International journal of clinical pharmacology, therapy and toxicology : (1980); ISSN 0174-4879; Coden IJCPB5; Allemagne; Da. 1991; Vol. 29; No. 8; Pp. 314-322; Bibl. 1 p.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Antiparkinsonien; Stimulant dopaminergique; Association médicamenteuse; Forme pharmaceutique; Traitement; Chimiothérapie; Homme; Système nerveux pathologie; Récepteur dopaminergique D2; Forme libération contrôlée; Parkinson maladie; Essai thérapeutique contrôlé; Dopa; Bromocriptine; Essai clinique</FD>
<ED>Antiparkinson agent; Dopamine agonist; Drug combination; Dosage form; Treatment; Chemotherapy; Human; Nervous system diseases; D2 Dopamine receptor; Controlled release form; Parkinson disease; Controlled therapeutic trial; Dopa; Bromocryptine; Clinical trial</ED>
<SD>Antiparkinsoniano; Estimulante dopaminérgico; Asociación medicamentosa; Forma farmacéutica; Tratamiento; Quimioterapia; Hombre; Sistema nervioso patología; Receptor dopaminérgico D2; Forma liberación controlada; Parkinson enfermedad; Ensayo terapéutico controlado; Dopa; Ensayo clínico</SD>
<LO>INIST-15902</LO>
<ID>91-0549078</ID>
</server>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001B73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:91-0549078
|texte= Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study
}}
| This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024 |  |
